New York (AFP) – The Pfizer and Johnson & Johnson (J&J) laboratories reported on Monday that they began work on a new version of their anticovid vaccines aimed specifically at the omicron variant, in case the current ones are not effective enough.
“There are still many things that are unknown” about the new variant, first detected in South Africa and considered “worrisome” by the WHO, said the executive director of the US pharmaceutical company Pfizer, Albert Bourla on Monday.
“We will know the essentials of what we need to know in a few weeks,” he added in an interview with the US network CNBC.
Trials will be conducted to evaluate the efficacy of current omicron vaccines.